Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.

Biomarkers in medicine - 1 Aug 2010

Jiang Yixing, Mackley Heath, Cheng Hua, Ajani Jaffer A

Abstract excerpt

Ras protein is a downstream regulator of multiple cellular receptor tyrosine kinases, mediating cell growth, transformation and maintenance of the malignant phenotype in several human cancers. Oncogenic gain-of-function mutations in ras frequently occur in colorectal cancer, non-small-cell lung c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 20701442
DOI: 10.2217/bmm.10.74

Genes

EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20701442-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.PMID 20701442Read ↗

Oncogenic mutations as predictive factors in colorectal cancer.Semantic proximity Read ↗

RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.Semantic proximity Read ↗

Ras in digestive oncology: from molecular biology to clinical implications.Semantic proximity Read ↗

K-ras mutations in colorectal cancer: a practice changing discovery.Semantic proximity Read ↗

Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.Semantic proximity Read ↗

KRAS and BRAF: drug targets and predictive biomarkers.Semantic proximity Read ↗

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancerSemantic proximity Read ↗

Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.